Cargando…

NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell Proliferation

SIMPLE SUMMARY: Tumor dormancy is a state in which some cancer cells are dormant by less cell proliferation, and are resistant to treatments, thus leading to late recurrence. As nuclear receptor subfamily 2 group F member 1 (NR2F1) is a biomarker of dormancy shown in experimental settings, we studie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Rongrong, Roy, Arya Mariam, Tokumaru, Yoshihisa, Gandhi, Shipra, Asaoka, Mariko, Oshi, Masanori, Yan, Li, Ishikawa, Takashi, Takabe, Kazuaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220877/ https://www.ncbi.nlm.nih.gov/pubmed/35740627 http://dx.doi.org/10.3390/cancers14122962

Ejemplares similares

CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future
por: Asaoka, Mariko, et al.
Publicado: (2020)

Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Enhanced Thermogenesis in Triple-Negative Breast Cancer Is Associated with Pro-Tumor Immune Microenvironment
por: Gandhi, Shipra, et al.
Publicado: (2021)

Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer
por: Oshi, Masanori, et al.
Publicado: (2022)

High Expression of microRNA-143 is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020)

M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients
por: Oshi, Masanori, et al.
Publicado: (2020)

Development of a novel BRCAness score that predicts response to PARP inhibitors
por: Oshi, Masanori, et al.
Publicado: (2022)

Annexin A1 Expression Is Associated with Epithelial–Mesenchymal Transition (EMT), Cell Proliferation, Prognosis, and Drug Response in Pancreatic Cancer
por: Oshi, Masanori, et al.
Publicado: (2021)

High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Intra-Tumoral Angiogenesis Is Associated with Inflammation, Immune Reaction and Metastatic Recurrence in Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Abundance of Microvascular Endothelial Cells Is Associated with Response to Chemotherapy and Prognosis in Colorectal Cancer
por: Oshi, Masanori, et al.
Publicado: (2021)

Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival
por: Oshi, Masanori, et al.
Publicado: (2021)

Left sided breast cancer is associated with aggressive biology and worse outcomes than right sided breast cancer
por: Abdou, Yara, et al.
Publicado: (2022)

Intratumoral Tumor Infiltrating Lymphocytes (TILs) are Associated With Cell Proliferation and Better Survival But Not Always With Chemotherapy Response in Breast Cancer
por: Wu, Rongrong, et al.
Publicado: (2023)

Biologically Aggressive Phenotype and Anti-cancer Immunity Counterbalance in Breast Cancer with High Mutation Rate
por: Takahashi, Hideo, et al.
Publicado: (2020)

Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment
por: Takeshita, Takashi, et al.
Publicado: (2022)

Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Should we target “intermediate expression” of HER2 in older estrogen receptor positive patients?
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020)

High G2M Pathway Score Pancreatic Cancer is Associated with Worse Survival, Particularly after Margin-Positive (R1 or R2) Resection
por: Oshi, Masanori, et al.
Publicado: (2020)

A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2021)

Intratumoral Adipocyte-High Breast Cancer Enrich for Metastatic and Inflammation-Related Pathways but Associated with Less Cancer Cell Proliferation
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020)

ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC)
por: Oshi, Masanori, et al.
Publicado: (2020)

Enhanced DNA Repair Pathway is Associated with Cell Proliferation and Worse Survival in Hepatocellular Carcinoma (HCC)
por: Oshi, Masanori, et al.
Publicado: (2021)

Low expression of miR-29a is associated with aggressive biology and worse survival in gastric cancer
por: Tokumaru, Yoshihisa, et al.
Publicado: (2021)

High Expression of miR-34a Associated with Less Aggressive Cancer Biology but Not with Survival in Breast Cancer
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020)

G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

APOBEC3-Mediated RNA Editing in Breast Cancer is Associated with Heightened Immune Activity and Improved Survival
por: Asaoka, Mariko, et al.
Publicado: (2019)

A Novel Four-Gene Score to Predict Pathologically Complete (R0) Resection and Survival in Pancreatic Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

MYC Targets Scores Are Associated with Cancer Aggressiveness and Poor Survival in ER-Positive Primary and Metastatic Breast Cancer
por: Schulze, Amy, et al.
Publicado: (2020)

Contribution of Immune Cells to Glucocorticoid Receptor Expression in Breast Cancer
por: Gandhi, Shipra, et al.
Publicado: (2020)

The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

The Role of the Microbiome on the Pathogenesis and Treatment of Colorectal Cancer
por: Yu, Irene, et al.
Publicado: (2022)

Urine as a Source of Liquid Biopsy for Cancer
por: Oshi, Masanori, et al.
Publicado: (2021)

Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival
por: Okano, Maiko, et al.
Publicado: (2019)

Organoids Are Limited in Modeling the Colon Adenoma–Carcinoma Sequence
por: Tokumaru, Yoshihisa, et al.
Publicado: (2021)

Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor
por: Takeshita, Takashi, et al.
Publicado: (2019)

GALNT1 Expression Is Associated with Angiogenesis and Is a Prognostic Biomarker for Breast Cancer in Adolescents and Young Adults (AYA)
por: Oshi, Masanori, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1ps5b9b50aqmvhju904lvf5248